The BAFF/APRIL system in SLE pathogenesis
Fabien B. Vincent(Monash Medical Centre), Fabienne Mackay(QIMR Berghofer Medical Research Institute), Eric F. Morand(Novartis (Switzerland)), Pascal Schneider(Forschungszentrum Jülich)
Cited by 441
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
|Science|1996|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726